Browse Studies — Arctuva

Phase 2

A Phase 2b/3, Quadruple-Blinded, Randomized, Placebo-Controlled Study of PORT-77 Administered Orally to Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria and an Open-Label Extension

PATHWAY is a Phase 2b/3 clinical study with an Open-Label Extension (OLE). It tests PORT-77 in patients with EPP, EPP2, and XLP. The study has three parts: P…

Erythropoietic Protoporphyria (EPP)X-Linked Protoporphyria (XLP)EPP2

Estimated

~$75 – $2,800

Actual pay is set by the research site.